Centre for Global Child Health, Hospital for Sick Children, Toronto, Ontario, Canada.
Nutrition and Clinical Services Division, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr, b), Dhaka, Bangladesh.
J Nutr. 2021 Nov 2;151(11):3361-3378. doi: 10.1093/jn/nxab265.
Variability in the 25-hydroxyvitamin D [25(OH)D] response to prenatal and postpartum vitamin D supplementation is an important consideration for establishing vitamin D deficiency prevention regimens.
We aimed to examine interindividual variation in maternal and infant 25(OH)D following maternal vitamin D supplementation.
In a randomized trial of maternal vitamin D supplementation (Maternal Vitamin D for Infant Growth Trial), healthy pregnant women (n = 1300) received a prenatal cholecalciferol (vitamin D-3) dose of 0, 4200, 16,800, or 28,000 IU/wk from 17 to 24 wk of gestation followed by placebo to 6 mo postpartum. A fifth group received 28,000 IU cholecalciferol/wk both prenatally and postpartum. In a subset of participants, associations of 25(OH)D with hypothesized explanatory factors were estimated in women at delivery (n = 655) and 6 mo postpartum (n = 566), and in their infants at birth (n = 502) and 6 mo of age (n = 215). Base models included initial 25(OH)D and supplemental vitamin D dose. Multivariable models were extended to include other individual characteristics and specimen-related factors. The model coefficient of determination (R2) was used to express the percentage of total variance explained.
Supplemental vitamin D intake and initial 25(OH)D accounted for the majority of variance in maternal 25(OH)D at delivery and postpartum (R2 = 70% and 79%, respectively). Additional characteristics, including BMI, contributed negligibly to remaining variance (<5% increase in R2). Variance in neonatal 25(OH)D was explained mostly by maternal delivery 25(OH)D and prenatal vitamin D intake (R2 = 82%). Variance in 25(OH)D in later infancy could only partly be explained by numerous biological, sociodemographic, and laboratory-related characteristics, including feeding practices (R2 = 43%).
Presupplementation 25(OH)D and vitamin D supplemental dose are the major determinants of the response to maternal prenatal vitamin D intake. Vitamin D dosing regimens to prevent maternal and infant vitamin D deficiency should take into consideration the mean 25(OH)D concentration of the target population.
产前和产后补充维生素 D 时 25-羟维生素 D [25(OH)D] 的反应存在个体差异,这是制定维生素 D 缺乏预防方案的一个重要考虑因素。
我们旨在研究母亲补充维生素 D 后母婴 25(OH)D 的个体差异。
在一项母亲维生素 D 补充的随机试验(婴儿生长的母亲维生素 D 试验)中,1300 名健康孕妇从妊娠 17 周到 24 周接受 0、4200、16800 或 28000IU/周的胆钙化醇(维生素 D3)剂量,然后在产后 6 个月给予安慰剂。第五组孕妇在产前和产后均接受 28000IU/周的胆钙化醇。在部分参与者中,在分娩时(n=655)和产后 6 个月(n=566)的女性以及出生时(n=502)和 6 个月大(n=215)的婴儿中,估计了 25(OH)D 与假设的解释因素之间的关联。基础模型包括初始 25(OH)D 和补充维生素 D 剂量。多变量模型扩展到包括其他个体特征和标本相关因素。模型决定系数(R2)用于表示总方差的解释百分比。
补充维生素 D 摄入量和初始 25(OH)D 分别占分娩时和产后母亲 25(OH)D 变异的大部分(R2 分别为 70%和 79%)。其他特征,包括 BMI,对剩余变异的贡献微不足道(R2 增加<5%)。新生儿 25(OH)D 的变异性主要由产妇分娩时的 25(OH)D 和产前维生素 D 摄入量解释(R2=82%)。在婴儿后期,25(OH)D 的变异性只能部分用许多生物学、社会人口学和实验室相关特征来解释,包括喂养方式(R2=43%)。
预补充 25(OH)D 和维生素 D 补充剂量是母体产前维生素 D 摄入反应的主要决定因素。预防母婴维生素 D 缺乏的维生素 D 给药方案应考虑目标人群的平均 25(OH)D 浓度。